Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
144.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
11
11 articles ont été cités au moins 11fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 241
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
16
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
11
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Inserm · Centre Hospitalier Universitaire de Limoges · Université de Limoges
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Characterization of challenging forensic DNA traces using advanced molecular technologies
2025ArticleInternational Journal of Legal Medicine
Confirmation of Psoriasis Susceptibility Loci on Chromosome 6p21 and 20p13 in French Families
2007ArticleJournal of Investigative Dermatology
The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy.
2007ArticleNature Genetics
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
SGSM ONCO
CHP SAINT GREGOIRE AVENUE SAINT VINCENT, 35760 ST GREGOIRE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Proceedings of the National Academy of Sciences of the United States of America · 1998
Rheumatoid arthritis (RA), the most common autoimmune disease, is associated in families with other autoimmune diseases, including insulin-dependent diabetes mellitus (IDDM). Its genetic component has been suggested by familial aggregation (λs = 5), twin studies, and segregation analysis. HLA , which is the only susceptibility locus known, has been estimated to account for one-third of this component. The aim of this paper was to identify new RA loci. A genome scan was performed with 114 European Caucasian RA sib pairs from 97 nuclear families. Linkage was significant only for HLA ( P < 2.5⋅10 −5 ) and nominal for 19 markers in 14 other regions ( P < 0.05). Four of the loci implicated in IDDM potentially overlap with these regions: the putative IDDM6, IDDM9, IDDM13 , and DXS998 loci. The first two of these candidate regions, defined in the RA genome scan by the markers D18S68-D18S61-D18S469 (18q22–23) and D3S1267 (3q13), respectively, were studied in 194 additional RA sib pairs from 164 nuclear families. Support for linkage to chromosome 3 only was extended significantly ( P = 0.002). The analysis of all 261 families provided a linkage evidence of P = 0.001 and suggested an interaction between this putative RA locus and HLA . This locus could account for 16% of the genetic component of RA. Candidate genes include those coding for CD80 and CD86, molecules involved in antigen-specific T cell recognition. In conclusion, this first genome scan in RA Caucasian families revealed 14 candidate regions, one of which was supported further by the study of a second set of families.
Nature genetics · 2007
Journal of the European Academy of Dermatology and Venereology : JEADV · 2015
AbstractBackgroundPrevious studies have demonstrated that patients with psoriasis have higher rates of comorbidities compared to the general population. Despite the clinical and economic burden of psoriatic disease, there have been few large‐scale observational studies focused on this condition.ObjectiveTo assess rates of cardiovascular, autoimmune, infectious and other conditions in patients with psoriasis or psoriatic arthritis (PSA).MethodsThe data for this retrospective study were obtained from the Clinical Practice Research Datalink (CRPD). Cohorts of patients with psoriasis (n = 27 672; mild, n = 22 174, severe, n = 5498) and PSA (n = 1952) were generated based on the diagnosis made by general practitioner or specialist recorded in CPRD between 2006 and 2010. Frequencies of comorbidities at baseline and incidence rate ratios (IRR) of medical conditions occurring during follow‐up were calculated and compared between groups. Cox proportional hazard models were employed to compare hazard ratios (HR) of comorbidities across the same subpopulations previously described.ResultsSignificant differences in the unadjusted risk of cardiovascular disease, hyperlipidaemia, diabetes, skin cancer and autoimmune diseases were observed between patients with differing severity of psoriasis or between PSA and psoriasis patients. The adjusted HR analyses confirmed patients with severe psoriasis had significantly higher rates of several conditions including diabetes (1.23; 95% CI: 1.01–1.51) and rheumatoid arthritis (2.88; 95% CI: 2.25–3.67) compared to patients with mild psoriasis. Patients with PSA had significantly higher adjusted rates of hypertension (1.30; 95% CI: 1.01–1.68), rheumatoid arthritis (6.93; 95% CI: 5.45–8.80) and ankylosing spondylitis (6.98; 95% CI: 2.37–20.58) compared to those with severe psoriasis.ConclusionPatients with mild psoriasis are less affected by comorbid conditions than those with severe psoriasis, and patients with psoriasis are less affected by comorbidities than those with PSA. Given the differences observed across severities of psoriasis and between psoriasis and PSA, each patient subgroup should be taken into consideration in clinical practice and future research.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of investigative dermatology · 2007 · Journal Article
Lesueur F, Bouadjar B, Lefèvre C, Jobard F, et al.
Proceedings of the National Academy of Sciences of the United States of America · 1998 · Journal Article
Cornélis F, Fauré S, Martinez M, Prud'homme JF, et al.
Orthopaedics & traumatology, surgery & research : OTSR · 2024 · Journal Article
Pluchon JP, Gérard R, Stindel E, Lefèvre C, et al.
Nature genetics · 2007 · Journal Article
Fischer J, Lefèvre C, Morava E, Mussini JM, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2015 · Journal Article
Edson-Heredia E, Zhu B, Lefevre C, Wang M, et al.
Trials · 2023 · Clinical Trial Protocol
Doumen M, De Meyst E, Lefevre C, Pazmino S, et al.
Revue du rhumatisme (English ed.) · 1997 · Journal Article
Le Nen D, Saraux A, Yaacoub C, Hu W, et al.
Clinical and experimental dermatology · 1988 · Journal Article
Francès C, Branchet MC, Blétry O, Lefevre C, et al.
Trials · 2023 · Clinical Trial Protocol
Doumen M, De Meyst E, Lefevre C, Pazmino S, et al.